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of illness, disability and even death. In some countries, 
adverse drug reactions (ADRs) rank among the top 10 
leading causes of mortality. In order to prevent or to 
reduce harm to patients and thus improve public health, 
mechanisms for evaluating and monitoring the safety of 
medicines in clinical use are vital.[1] Pharmacovigilance 
programs in the next 10 years, describe in brief the potential 
implications of such trends on the evolution of the science. 
These days pharmacovigilance is facing lots of challenges 
to develop better health care systems in this global pitch. 
Major challenges are globalization, web-based sales and 
information, broader safety concerns, public health versus 
pharmaceutical industry economic growth, monitoring of 
INTRODUCTION
Drug safety and pharmacovigilance remains a dynamic 
clinical and scientific discipline. Pharmacovigilance is 
defined by the World Health Organization (WHO) as ‘the 
science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any 
other drug-related problem’;[1] it plays a vital role in ensuring 
that doctors, together with the patient, have enough 
information to make a decision when it comes to choosing 
a drug for treatment.[2] However, despite all their benefits, 
evidence continues to get those bigger adverse reactions to 
medicines which are common, yet often preventable, cause 
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Pharmacovigilance is like a sunshade to describe the processes for monitoring and evaluating ADRs and it 
is a key component of effective drug regulation systems, clinical practice and public health programmes. The 
number of Adverse Drug Reactions (ADRs) reported resulted in an increase in the volume of data handled, and 
to understand the pharmacovigilance, a high level of expertise is required to rapidly detect drug risks as well 
as to defend the product against an inappropriate removal. The current global network of pharmacovigilance 
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review. This would consider litigious and important drug safety issues that have the potential to affect public 
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detect adverse drug events that were previously either unknown or poorly understood. Pharmacovigilance is 
an important and integral part of clinical research and these days it is growing in many countries. Today many 
pharmacovigilance centers are working for drug safety monitoring in this global pitch, however, at the turn of 
the millennium pharmacovigilance faces major challenges in aspect of better safety and monitoring of drugs. In 
this review we will discuss about drug safety, worldwide pharmacovigilance centers and their role, benefits and 
challenges of pharmacovigilance and its future consideration in healthcare sectors.
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established products, developing and emerging countries, 
attitudes and perceptions to benefit and harm, outcomes 
and impact.[3] 
HISTORICAL PERSPECTIVES OF WHO - DRUG 
SAFETY MONITORING
In 2002, more than 65 countries have their own 
pharmacovigilance centers. Membership of the WHO 
for International Drug Monitoring is coordinated by 
the WHO Collaborating Centre for International Drug 
Monitoring, known as the Uppsala Monitoring Centre 
(UMC). Pharmacovigilance is now firmly based on sound 
scientific principles and is integral to effective clinical 
practice. The discipline needs to develop further to meet 
public expectations and the demands of modern public 
health. The Sixteenth World Health Assembly adopted a 
resolution (WHA 16.36)[5] that reaffirmed the need for early 
action in regard to rapid dissemination of information on 
adverse drug reactions and led later to creation of the WHO 
Pilot Research Project for International Drug Monitoring. 
The purpose of this was to develop a system, applicable 
internationally, for detecting previously unknown or poorly 
understood adverse effects of medicines.[6]
WORLDWIDE SOLDIERS OF 
PHARMACOVIGILANCE 
A complex and vital relationship exists between wide ranges 
of partners in the practice of drug safety monitoring. These 
partners must jointly anticipate, understand and respond 
to the continually increasing demands and expectations of 
the public, health administrators, policy officials, politicians 
and health professionals.
The Quality Assurance and Safety: The team is a part of the 
Department of Essential Drugs and Medicines Policy, 
within the WHO Health Technology and Pharmaceuticals 
cluster. The purpose of the department is to help save lives 
and improve health by closing the huge gap between the 
potential that essential drugs have to offer and the reality 
that for millions of people, particularly the poor and 
disadvantaged, medicines are unavailable, unaffordable, 
unsafe or improperly used.[7] 
The Uppsala Monitoring Centre: The principal function of the 
Uppsala Monitoring Centre is to manage the international 
database of ADR reports received from National Centers.  [8] 
The UMC has established standardized reporting by 
all National Centers and has facilitated communication 
between countries to promote rapid identification of 
signals. 
The National Pharmacovigilance Centers: National Centers have 
played a significant role in increasing public awareness of 
drug safety. This development is partly attributable to the 
fact that many national and regional centers are housed 
within hospitals, medical schools or poison and drug 
information centers, rather than within the confines of 
a drug regulatory authority. Major centers in developed 
countries have established active surveillance programmes 
using record linkage and prescription event monitoring 
systems (PEM) to collect epidemiological information 
on adverse reactions to specific drugs. Such systems have 
already been implemented in New Zealand, the United 
Kingdom, Sweden and the United States of America. The 
entire cost of a pharmacovigilance system, compared with 
the national expenditure on medicines or the cost of ADRs 
to the nation is very small indeed.[9,10]
Hospitals and Academia: A number of medical institutions 
have developed adverse reaction and medication error close 
watch systems in their clinics, wards and emergency rooms. 
Case-control studies and other pharmacoepidemiological 
methods have increasingly been used to estimate the harm 
associated with medicines once they have been marketed. 
Academic centers of pharmacology and pharmacy have 
played an important role through teaching, training, 
research, policy development, clinical research, ethics 
committees (institutional review boards) and the clinical 
services they provide.[11-13] 
Health Professionals: Originally physicians were the only 
professionals invited to report as judging whether disease 
or medicine causes a certain symptom by exercising the 
skill of differential diagnosis. Today, different categories 
of health professionals will observe different kinds of drug 
related problems.[14,15]
Patients: Only a patient knows the actual benefit and 
harm of a medicine taken. Direct patient participation 
in the reporting of drug related problems will increase 
the efficiency of the pharmacovigilance system and 
compensate for some of the shortcomings of systems 
based on reports from health professionals only.
PHARMACOVIGILANCE IN DRUG REGULATION
Pharmacovigilance programs made strong by links with 
regulators. Regulators understand that pharmacovigilance 
plays a specialized and pivotal role in ensuring ongoing 
safety of medicinal products.
Clinical trial regulation: In recent years there has been a 
substantial increase in the number of clinical trials in J Young Pharm Vol 2 / No 3  317
developed and developing countries. In their approval 
of clinical trials, regulatory bodies look at safety and 
efficacy of new products under investigation. Safety 
monitoring of medicines in common use should be an 
integral part of clinical practice. Education and training 
of health professionals in medicine safety, exchange of 
information between national pharmacovigilance centers, 
the coordination of such exchange, and the linking of 
clinical experience of medicine safety with research and 
health policy, all serve to enhance effective patient care. 
A regular flow and exchange of information in this way 
means that national pharmacovigilance programmes are 
ideally placed to identify gaps in our understanding of 
medicine-induced diseases.[1]
Post marketing safety drug monitoring: These includes detection 
of drug interactions, measuring the environmental burden 
of medicines used in large populations, assessing the 
contribution of ‘inactive’ ingredients to the safety profile, 
systems for comparing safety profiles of similar medicines, 
surveillance of the adverse effects on human health of 
drug residues in animals, e.g. antibiotics and hormones. 
The Council for International Organizations of Medical 
Sciences (CIOMS) report on benefit-risk assessment of 
medicines after marketing has contributed to a more 
systematic approach to determining the merit of available 
medicines.[16]
Pharmacovigilance in national drug Policy: The provision 
of good quality, safe and effective medicines and 
their appropriate use is the responsibility of national 
governments. Multidisciplinary collaboration is of great 
importance in particular, links need to be forged between 
various departments of the ministry of health and also 
with other stakeholders, such as the pharmaceutical 
industry, universities, nongovernmental organizations 
(NGOs) and those professional associations having 
responsibility for education on rational use of medicines 
and pharmacotherapy monitoring.
Pharmacovigilance in Disease Control Public Health Programmes: 
The monitoring of medicine safety in countries where 
there is no regulatory or safety monitoring system in 
place, or in remote areas with little or no health care 
surveillance or infrastructure, has been identified as a 
matter for concern. The problems are especially apparent 
in situations that involve the use of medicines in specific 
communities, for example, for the treatment of tropical 
diseases such as malaria, leishmaniasis and schistosomiasis, 
and for the treatment of HIV/AIDS and tuberculosis. 
Pharmacovigilance should be a priority for every country 
with a public health disease control programs.[1]
PHARMACOVIGILANCE AND INTERNATIONAL 
HEALTH
The current global network of pharmacovigilance centers 
is coordinated by the Uppsala Monitoring Centre, would 
be strengthened by an independent system of review. 
This would consider contentious and important drug 
safety issues that have the potential to affect public 
health adversely beyond national boundaries. The Erice 
Declaration provides a framework of values and practice 
for collection, analysis and subsequent communication of 
drug safety issues. Today, the burden of ADRs on public 
health despite the progress in pharmacovigilance that 
has been made, the burden on public health of ADRs 
remains significant.[17] Pharmacoeconomic studies on 
the costs of adverse reactions suggest that governments 
pay considerable amounts from health budgets towards 
covering costs associated with them.[18] However, it 
has become increasingly clear that the safety profile of 
medicines is directly linked with socio-political, economic 
and cultural factors that in turn affect access to medicines, 
their utilization patterns and public perceptions of 
them.  [19,20]
Drug utilization: Drug utilization patterns are a major 
determinant in drug safety. For instance, the use of 
injectable medicines is more common in developing 
countries.[21] Direct advertizing to the consumer of 
prescription medicines has become commonplace in many 
countries. With this information patients feel more able to 
make their own therapeutic decisions, without assistance 
from doctor or pharmacist. The result has been increasing 
self medication, licit and illicit sale of medicines over the 
Internet, and over-prescribing by doctors on patients’ 
demand. This has had considerable effect on increased 
prescribing.[22,23] Such public health programmes, however, 
need not focus only on patients but could be used for 
the benefit of the general public as well. Such awareness-
building and educational initiatives should also include 
children and elderly populations and could be greatly 
facilitated through partnerships with the media, educational 
institutions, governmental and non-governmental 
organizations. The success of WHO International Drug 
Monitoring Programmes is entirely dependent on the 
contributions of national pharmacovigilance centers. 
Ideally every country should have a pharmacovigilance 
centre.[1]
THE ERICE DECLARATION
The Erice Declaration represented significant progress 
in the light of these changes for pharmacovigilance The 
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Declaration challenges all the players like public health 
administration, health professionals, the pharmaceutical 
industry, government, drug regulators, the media, consumers 
to strive towards the highest ethical, professional and 
scientific standards in protecting and promoting safe use of 
medicines. The Declaration urges governments and others 
involved in determining policies relating to the benefit, harm, 
effectiveness and risk of medicines to account for what they 
communicate to the public and patients. 
Challenges for the Erice Declaration: There are several challenges 
facing pharmacovigilance programmes in achieving the 
aspirations of the Erice Declaration. Like The difficulties 
and risks in communicating conflicting or contentious 
messages to the public. For instance, during the course 
of immunization programmes, communication of new 
safety concerns associated with the vaccine(s) or with 
programmatic errors may result in a dramatic fall in 
coverage. Nonetheless, an approach of secrecy in such 
circumstances is likely to erode public trust and confidence, 
and it fails to respect the rights of the public to participate 
in decision-making. Not only do facts and figures need to 
be shared with the public, but also the process by which 
the data is assessed and how decisions are made should 
be shared openly. Another challenge is Communication 
between national drug regulatory authorities and national 
pharmacovigilance centers needs to be improved so 
that regulatory decisions with possible international 
implications are rapidly communicated to regulators, to 
avoid widespread public concern or panic.[24]
INTERNATIONAL RESPONSE TO DRUG SAFETY 
ISSUES
Certain safety issues are likely to have a global impact 
with possibly serious consequences for public health. 
When this happens, a cohesive international assessment 
and response is needed. The WHO has supported the 
creation of an independent advisory panel composed 
of a broad spectrum of medical disciplines including 
clinical pharmacologists, regulators, academics and 
epidemiologists. The functions of this panel will be 
to provide advice to WHO on safety issues relating to 
medicinal products, including its Collaborating Centre 
for International Drug Monitoring and through it to the 
Member States of WHO.[25]
NEWS BROADCAST RELATED TO PANDEMIC 
PHARMACOVIGILANCE UPDATE
The benefit and risk balance of the pandemic vaccines and 
antiviral used for the current H1N1 influenza pandemic 
continues to be positive. To date, no unexpected serious 
safety issues have been identified. The most frequent 
adverse reactions that have been reported are non-serious 
and as expected. The EMEA issued a press release on 
November 2009 reaffirming the efficacy and safety of the 
centrally authorized vaccines. With vaccination campaigns 
ongoing in the European Union, it is estimated that about 
10 million people have been vaccinated so far. The vaccine 
adverse effects reported so far have mainly been symptoms 
such as fever, nausea, headache, allergic reactions and 
injection site reactions, confirming the expected safety 
profile of the three vaccines. New clinical trial data showed 
greater incidence of fever following the second dose of 
Pandemrix in infants from 6 months to 35 months. An 
assessment of these data is ongoing.[26]
CONSIDERATIONS FOR THE FUTURE AND ITS 
CHALLENGES 
Some of the serious challenges facing pharmacovigilance 
programmes in the next ten years, describing in brief the 
potential implications of such trends on the evolution of 
the science.
Some key points for future consideration which may be 
improved to make better pharmacovigilance practice:
1.  Pharmacovigilance should be less focused on finding 
harm and more on extending knowledge of safety.
2.  Complex risk-benefit decisions are amenable to, and 
likely to be improved by, the use of formal decision 
analysis.
3.  Pharmacovigilance should operate in a culture of 
scientific development. This requires the right balance 
of inputs from various disciplines, a stronger academic 
base, and greater availability of basic training, and 
resource which is dedicated to scientific strategy.
4.  Systematic audit of pharmacovigilance processes and 
outcomes should be developed and implemented based 
on agreed standards (‘good pharmacovigilance practice’).
Some Major challenges face pharmacovigilance are as 
follows:
Globalization: The globalization of drug distribution and the 
increased exposure of massive populations to large volumes 
of medicines. These include novel chemical entities used 
for symptomatic relief and lifestyle modification as well 
as medicines used in developing countries to curb the 
prevalence of pandemic diseases such as HIV/AIDS, 
malaria and tuberculosis. 
Web-based sales and information: The Internet, in addition to 
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its many benefits, has also facilitated the uncontrolled sale 
of medicines across national borders. Drug information in 
all forms and with varying levels of accuracy is distributed 
internationally through this medium. Such information 
covers prescription drugs, unregistered medicines, highly 
controlled substances and traditional and herbal medicines 
with questionable safety, efficacy and quality. 
Broader safety concerns: The scope of pharmacovigilance 
continues to broaden as the array of medicinal products 
grows. There is a realization that drug safety is more than the 
monitoring, detection and assessment of ADRs occurring 
under clearly defined conditions and within a specific dose 
range. Rather, it is closely linked to the patterns of drug use 
within society. Problems resulting from irrational drug use, 
overdoses, polypharmacy and interactions, increasing use 
of traditional and herbal medicines with other medicines, 
illegal sale of medicines and drugs of abuse over the 
Internet increasing self medication practices substandard 
medicines, medication errors, lack of efficacy are all within 
the domain of pharmacovigilance. Current systems need 
to evolve in order to address this broad scope adequately.
Public health versus pharmaceutical industry economic growth: There 
may be shortcomings and at times conflicting interests 
within the pharmaceutical industry when dealing with 
public health concerns arising from drug safety issues. 
The industry needs to overcome weaknesses in safety 
monitoring during clinical trials and post-marketing 
surveillance. 
Monitoring of  established products: The generic sector of the 
pharmaceutical industry has not fully recognized and its 
responsibility to continuously monitor the safety of its 
products throughout the world. There is the erroneous 
belief that generic drugs are inherently safe even when 
they interact with other medicines. The generic sector is 
the largest supplier of essential drugs.
Attitudes and perceptions to benefit and harm: These trends 
have dramatically changed the way in which medicines 
are used by society. Healthcare providers, patients and the 
public have responded in different ways to these changing 
trends as has been described in previous chapters. Their 
perception of benefit and harm and the level of acceptable 
risk for medicines in the face of these rapid developments 
have not been considered in a meaningful way. The harm 
caused by medicines has been shown to be significant. 
Morbidity and mortality from drug-induced diseases are 
only recently being recognized as an important item on 
the public health agenda in developed and developing 
countries.
Outcomes and Impact: Along with increased public awareness 
over safety of medicines, there is an increasing public stare 
on the performance of the health professions, industry 
and regulators. Increased accountability must lead to more 
research into the effectiveness of pharmacovigilance and its 
place in improving public perception. A major focus must 
be to empower health practitioners and patients themselves 
with useful information that improves individual therapy, 
aids the diagnosis and management of medicine-induced 
disease, and generally leads to a reduction of iatrogenic 
diseases.[27-29]
CONCLUSION
Pharmacovigilance continues to play a crucial role in 
meeting the challenges posed by the ever increasing range 
and potency of medicines, all of which carry an inevitable 
and some- times unpredictable potential for harm. 
When adverse effects and toxicity do appear, especially 
when previously unknown, it is essential that these are 
reported, analyzed and their significance is communicated 
effectively to the audience having knowledge to interpret 
the information. For all medicines, there is a trade-off 
between the benefits and the potential for harm. The harm 
can be minimized by ensuring that medicines of good 
quality, safety and efficacy are used rationally, and that the 
expectations and concerns of the patient are taken into 
account when therapeutic decisions are made. To achieve 
this is to serve public health, and to foster a sense of trust 
among patients in the medicines they use that would extend 
the confidence in the health service in general, ensure that 
risks in drug use are anticipated and managed, provide 
regulators with the necessary information to amend the 
recommendations on the use of the medicines, improve 
communication between the health professionals and the 
public and educate health professionals to understand the 
effectiveness or risk of medicines that they prescribe.
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